Danaher Corp
DHRQ3 2024(DHR Q2 FY2024)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$737.2M
AI Revenue (Q)
$57.4M
Total Revenue (Q)
$5.7B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q2 FY2024 (three-month period ended June 28, 2024). Total sales $5,743M. Segments: Biotechnology $1,713M, Life Sciences $1,770M, Diagnostics $2,260M. No AI revenue disclosure. Filing contains no AI-specific product or revenue mentions. Conservative 1% estimate. Math: ~$57M estimated / $5,743M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $5,743 [three-month period ended June 28, 2024]
10-Q Q2 FY2024, Consolidated Condensed Statements of Earnings
Biotechnology $1,713; Life Sciences $1,770; Diagnostics $2,260 [three-month period ended June 28, 2024]
10-Q Q2 FY2024, Note 6 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instruments
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix